Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q00987

UPID:
MDM2_HUMAN

ALTERNATIVE NAMES:
Double minute 2 protein; Oncoprotein Mdm2; RING-type E3 ubiquitin transferase Mdm2; p53-binding protein Mdm2

ALTERNATIVE UPACC:
Q00987; A6NL51; A8K2S6; Q13226; Q13297; Q13298; Q13299; Q13300; Q13301; Q53XW0; Q71TW9; Q8WYJ1; Q8WYJ2; Q9UGI3; Q9UMT8

BACKGROUND:
The E3 ubiquitin-protein ligase Mdm2, with aliases such as Double minute 2 protein and RING-type E3 ubiquitin transferase Mdm2, is crucial for ubiquitination processes, including the degradation of p53/TP53. Its activity is essential for the regulation of cell cycle checkpoints and apoptosis, acting through mechanisms that involve the ubiquitination and subsequent degradation of key cellular proteins.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in the pathogenesis of Lessel-Kubisch syndrome and its function in the ubiquitination pathway, targeting Mdm2 presents a promising avenue for therapeutic intervention. The protein's ability to regulate p53/TP53 and its involvement in cellular apoptosis and proliferation pathways highlight its therapeutic potential in combating diseases associated with cell cycle dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.